- Home
- NEPH vs BCTX Comparison
NEPH vs BCTX Comparison
Compare NEPH & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEPH
- BCTX
- Stock Information
- Founded
- NEPH 1997
- BCTX 2014
- Country
- NEPH United States
- BCTX Canada
- Employees
- NEPH N/A
- BCTX N/A
- Industry
- NEPH Medical/Dental Instruments
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- NEPH Health Care
- BCTX Health Care
- Exchange
- NEPH Nasdaq
- BCTX Nasdaq
- Market Cap
- NEPH 16.8M
- BCTX 15.8M
- IPO Year
- NEPH 2004
- BCTX N/A
- Fundamental
- Price
- NEPH $2.13
- BCTX $3.50
- Analyst Decision
- NEPH Buy
- BCTX Strong Buy
- Analyst Count
- NEPH 1
- BCTX 1
- Target Price
- NEPH $5.00
- BCTX $32.00
- AVG Volume (30 Days)
- NEPH 12.4K
- BCTX 40.5K
- Earning Date
- NEPH 05-08-2025
- BCTX 03-12-2025
- Dividend Yield
- NEPH N/A
- BCTX N/A
- EPS Growth
- NEPH N/A
- BCTX N/A
- EPS
- NEPH 0.01
- BCTX N/A
- Revenue
- NEPH $14,162,000.00
- BCTX N/A
- Revenue This Year
- NEPH $9.23
- BCTX N/A
- Revenue Next Year
- NEPH $12.99
- BCTX N/A
- P/E Ratio
- NEPH $298.53
- BCTX N/A
- Revenue Growth
- NEPH N/A
- BCTX N/A
- 52 Week Low
- NEPH $1.36
- BCTX $0.35
- 52 Week High
- NEPH $2.55
- BCTX $7.87
- Technical
- Relative Strength Index (RSI)
- NEPH 78.82
- BCTX 44.24
- Support Level
- NEPH $1.55
- BCTX $3.44
- Resistance Level
- NEPH $1.62
- BCTX $4.36
- Average True Range (ATR)
- NEPH 0.10
- BCTX 0.37
- MACD
- NEPH 0.06
- BCTX -0.10
- Stochastic Oscillator
- NEPH 87.79
- BCTX 11.11
About NEPH Nephros Inc.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.